Tofatib Treatment for IgG4-related Disease

Compared with cyclophosphamide, the efficacy and safety of tofacitinib in the treatment of active IgG4-related diseases were evaluated.

Inclusion Criteria:It meets the 2019 ACR/EULAR classification diagnostic criteria for IgG4 related diseases, and is an active IgG4-RD, defined as an IgG4-RD RI score ≥ 3 points when screeningExclusion Criteria:1. IgG4 related diseases endangering organ function or life;2. Only Mikulicz disease, no other internal organs involved;3. People with history of thrombotic disease or high risk of thrombosis;4. Have a history of malignant tumor;5. Active infection;6. Pregnant or lactating women;